Viewing Study NCT06376370



Ignite Creation Date: 2024-05-06 @ 8:24 PM
Last Modification Date: 2024-10-26 @ 3:27 PM
Study NCT ID: NCT06376370
Status: ENROLLING_BY_INVITATION
Last Update Posted: 2024-04-19
First Post: 2024-04-16

Brief Title: The Effect of a Computer-Assisted Rehabilitation Program on Epilepsy Patient
Sponsor: Selcuk University
Organization: Selcuk University

Study Overview

Official Title: The Effect of RehaCom Computer-Assisted Rehabilitation Program on Self-Management Cognitive Function and Quality of Life in Epilepsy Patients Randomized Controlled Study
Status: ENROLLING_BY_INVITATION
Status Verified Date: 2024-04
Last Known Status: None
Delayed Posting: No
If Stopped, Why?: Not Stopped
Has Expanded Access: False
If Expanded Access, NCT#: N/A
Has Expanded Access, NCT# Status: N/A
Acronym: None
Brief Summary: The aim of this study is to examine the effects of the RehaCom Computer-Assisted Rehabilitation Program Applied to Epilepsy Patients on Self-Management Cognitive Function and Quality of Life
Detailed Description: Modules designed to train cognitive abilities will be used under the supervision of a licensed researcher who is licensed to use the RehaCom application which is a computer-assisted cognitive rehabilitation program Researchers can select some modules based on each patients specific deficits meaning that deficits can be targeted and specifically trained Since the program will respond to the patients specific needs the activity may become easier or more difficult depending on the patients performance Epilepsy patients will be encouraged by researchers during the exercises and will be able to give feedback on progress at the end of the session After determining the appropriate time and day for each patient in the experimental group the intervention will continue for 6 weeks with 45-minute sessions once a week

Study Oversight

Has Oversight DMC: None
Is a FDA Regulated Drug?: False
Is a FDA Regulated Device?: False
Is an Unapproved Device?: None
Is a PPSD?: None
Is a US Export?: None
Is an FDA AA801 Violation?: None